These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
F13-16 |
||
(Address of principal executive offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-half of one redeemable warrant |
||||
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| ☒ | Smaller reporting company | |||||
| Emerging growth company | ||||||
Page |
||||||
Item 1. |
1 |
|||||
2 |
||||||
3 |
||||||
4 |
||||||
5 |
||||||
Item 2. |
17 |
|||||
Item 3. |
19 |
|||||
Item 4. |
20 |
|||||
Item 1. |
21 |
|||||
Item 1A. |
21 |
|||||
Item 2. |
21 |
|||||
Item 3. |
21 |
|||||
Item 4. |
21 |
|||||
Item 5. |
21 |
|||||
Item 6. |
22 |
|||||
23 |
||||||
September 30, 2021 |
||||
| ASSETS |
||||
| Current assets: |
||||
| Cash |
$ | |||
| |
|
|||
| Total current assets |
||||
| Deferred offering costs associated with proposed public offering |
||||
| |
|
|||
| Total assets |
$ | |||
| |
|
|||
| LIABILITIES AND SHAREHOLDER’S DEFICIT |
||||
| Current liabilities: |
||||
| Accounts payable |
$ | |||
| Accrued offering and formation costs |
||||
| Promissory note payable - related party |
||||
| |
|
|||
| Total current liabilities |
||||
| |
|
|
|
|
| Commitments and Contingencies (Note 5) |
|
|
|
|
| Shareholder’s Deficit: |
||||
| Preference shares, $ |
||||
| Class A ordinary shares, $ |
||||
| Class B ordinary shares, $ (1)(2) |
||||
| Additional paid-in capital |
||||
| Accumulated deficit |
( |
) | ||
| |
|
|||
| Total shareholder’s deficit |
( |
) | ||
| |
|
|||
| Total Liabilities and Shareholder’s Deficit |
$ |
|||
| |
|
|||
| (1) | This number includes an aggregate of up to ). On November 15, 2021, the underwriters fully exercised their over-allotment option; thus, these shares are |
| (2) | On September 17, 2021, our sponsor effected a surrender of |
For the three months ended September 30, 2021 |
For the period from March 5, 2021 (inception) through September 30, 2021 |
|||||||
| Formation costs |
$ |
$ |
||||||
| |
|
|
|
|||||
| Net loss |
$ |
( |
) |
$ |
( |
) | ||
| |
|
|
|
|||||
| Weighted average shares outstanding, basic and diluted (1)(2) |
||||||||
| |
|
|
|
|||||
| Basic and diluted net loss per share |
$ |
( |
) |
$ |
( |
) | ||
| |
|
|
|
|||||
| (1) | This number excludes an aggregate of up to ). On November 15, 2021, the underwriters fully exercised their over-allotment option; thus, these shares are |
| (2) | On September 17, 2021, our sponsor effected a surrender of |
Ordinary Shares |
Additional |
Total |
||||||||||||||||||
Class B |
Paid-In |
Accumulated |
Shareholder’s |
|||||||||||||||||
Shares |
Amount |
Capital |
Deficit |
Deficit |
||||||||||||||||
| Balance as of March 5, 2021 (inception) |
$ | $ | $ | $ | ||||||||||||||||
| Issuance of ordinary shares to Sponsor (1)(2) |
— | |||||||||||||||||||
| Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
| |
|
|
|
|
|
|
|
|
|
|||||||||||
| Balance as of June 30, 2021 |
( |
) |
( |
) | ||||||||||||||||
| Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
| |
|
|
|
|
|
|
|
|
|
|||||||||||
| Balance as of September 30, 2021 |
$ |
$ |
$ |
( |
) |
$ |
( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|
|
|||||||||||
| (1) | This number includes an aggregate of up to ). On November 15, 2021, the underwriters fully exercised their over-allotment option; thus, these shares are |
| (2) | On September 17, 2021, our sponsor effected a surrender of |
For the period from March 5, 2021 (inception) through September 30, 2021 |
||||
| Cash Flows from Operating Activities: |
||||
| Net loss |
$ | ( |
) | |
| Adjustments to reconcile net loss to net cash used in operating activities: |
||||
| Formation costs funded by note payable through Sponsor |
||||
| Formation costs paid in exchange for issuance of ordinary shares |
||||
| Changes in operating assets and liabilities: |
||||
| Accounts payable |
||||
| Accrued offering and formation costs |
||||
| |
|
|||
| Net cash used in operating activities |
( |
) | ||
| |
|
|||
| Cash Flows from Financing Activities: |
||||
| Proceeds from promissory note payable - related party |
||||
| Repayment of promissory note payable - related party |
( |
) | ||
| Offering costs paid |
( |
) | ||
| |
|
|||
| Net cash provided by financing activities |
||||
| |
|
|||
| Net increase in cash |
||||
| Cash - beginning of period |
||||
| |
|
|||
| Cash - end of period |
$ | |||
| |
|
|||
| Supplemental disclosure of noncash investing and financing activities: |
||||
| Deferred offering costs included in accounts payable |
$ | |||
| |
|
|||
| Deferred offering costs included in accrued offering and formation costs |
$ | |||
| |
|
|||
| Deferred offering costs paid through promissory note - related party |
$ | |||
| |
|
|||
| Issuance of Founder Shares in exchange for payment of deferred offering costs |
$ | |||
| |
|
|||
| Level 1: | Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. | |
| Level 2: | Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. | |
| Level 3: | Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. | |
| • | in whole and not in part; |
| • | at a price of $ |
| • | upon a minimum of |
| • | if, and only if the last reported sale price of Class A ordinary shares for any |
| • | in whole and not in part; |
| • | at a price of $ |
| • | if, and only if the Reference Value equals or exceeds $10.00 per share (as adjusted); and |
| • | if, and only if the Reference Value is less than $ |
| No. |
Description of Exhibit | |
| 31.1 | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 32.1 | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 101.INS | Inline XBRL Instance Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |
WORLDWIDE WEBB ACQUISITION CORP. | ||||||
| Date: December 6, 2021 | /s/ Daniel S. Webb | |||||
| Name: | Daniel S. Webb | |||||
| Title: | Chief Executive Officer and Chief Financial Officer | |||||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|